Related Experiment Video
Updated: Jun 11, 2026

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
MMP-12 Inhibitors Inverse Eosinophilic Inflammation-Mediated Bronchial Fibrosis in Murine Models of Pulmonary Airway
Chandra Sekhar Kathera1, Chandra Sekhar Yadavalli1, Anil Mishra1
1John W. Deming Department of Medicine, Tulane Eosinophilic Disorders Center (TEDC), Section of Pulmonary Diseases, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Abstract:
Matrix metalloproteinases (MMPs) are a major group of proteases known to regulate the turnover of the extracellular matrix (ECM). We observed that induced MMP-12 promotes eosinophilic inflammation-related epithelial cell mesenchymal transition (EMT), bronchial fibrosis, and airway obstruction in an allergen-exposed mouse model of chronic airway diseases in allergen-exposed mice and in airway-specific CC10-IL-13-overexpressed mice. Our histological analysis showed that the parabronchial and perivascular accumulation of eosinophils, fibroblasts, and collagen is significantly decreased in MMP-12-/- allergen-exposed mice and airway-specific rtTA-MMP-12-/-CC-10-IL-13-overexpressed mice compared to allergen-exposed wild-type mice and rtTA-CC10-IL-13-overexpressed mice. ELISA and Western blot analyses validated these histological findings, demonstrating that EMT and profibrotic protein levels were significantly decreased in allergen-challenged MMP-12-/- mice and rtTA-MMP-12-/-CC10-IL-13-overexpressed mice in comparison to the allergen-exposed wild-type mice and rtTA-CC10-IL-13-overexpressed mice. In addition, we also observed that allergen-challenged MMP-12-/- mice have improved resistance and compliance compared to allergen-challenged wild-type mice. Most importantly, we show that treatment with MMP-12 inhibitors (PF-00356231 and MMP408) restricts the induction and progression of bronchial fibrosis and airway restrictions in allergen-exposed mice and airway-specific rtTA-CC10-IL-13 mice compared to the respective control mice. Taken together, the novelty of these findings lie in the fact that induced MMP-12 regulates eosinophilic inflammation-induced bronchial fibrosis and associated airway restriction, which may be reduced by treatment with MMP-12 inhibitors.
Insights
Matrix metalloproteinase-12 (MMP-12) drives airway fibrosis and obstruction in chronic airway diseases. Inhibiting MMP-12 reduces these effects, offering a potential therapeutic strategy for related respiratory conditions.
Area of Science:
- Pulmonary Medicine
- Immunology
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) regulate extracellular matrix (ECM) turnover.
- MMP-12's role in chronic airway diseases, particularly eosinophilic inflammation, is not fully understood.
Purpose of the Study:
- To investigate the role of MMP-12 in promoting airway remodeling and obstruction.
- To evaluate the therapeutic potential of MMP-12 inhibitors in a mouse model of chronic airway disease.
Main Methods:
- Utilized allergen-exposed mouse models, including MMP-12 knockout and IL-13 overexpressing mice.
- Performed histological analysis, ELISA, and Western blot to assess inflammation, fibrosis, and epithelial-mesenchymal transition (EMT).
- Administered MMP-12 inhibitors (PF-00356231 and MMP408) to evaluate their efficacy.
Main Results:
- Induced MMP-12 promoted eosinophilic inflammation, EMT, bronchial fibrosis, and airway obstruction.
- MMP-12 deficiency significantly reduced eosinophil, fibroblast, and collagen accumulation.
- MMP-12 inhibition attenuated bronchial fibrosis and improved airway resistance and compliance.
Conclusions:
- MMP-12 is a key regulator of eosinophilic inflammation-induced bronchial fibrosis and airway obstruction.
- MMP-12 inhibitors demonstrate therapeutic potential for treating chronic airway diseases characterized by fibrosis and obstruction.
Related Concept Videos
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma I: Introduction
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

